# Opportunity #18: Research Participation & Clinical Trial Matching Platform

**Project**: Alpha1Life.com Enhancement
**Opportunity**: Clinical Trial Recruitment & Research Registry Integration
**Owner**: Mark Egly Foundation
**Created**: November 12, 2025
**Priority**: Must-Have (Year 1-2), Critical for Advancing Alpha-1 Research

---

## ğŸ“‹ Executive Summary

### The Problem

**Alpha-1 research is critically underfunded and slow.** Despite being one of the most common genetic diseases (100K-200K Americans affected), Alpha-1 receives disproportionately low research investment compared to other genetic conditions:

- **NIH funding**: $15M/year for Alpha-1 vs. $500M+ for cystic fibrosis (similar prevalence)
- **Clinical trial recruitment**: Slowest bottleneck in Alpha-1 research (trials fail due to under-enrollment)
- **Trial enrollment rate**: Only 5-10% of eligible patients participate in trials
- **Trial awareness**: 80% of Alpha-1 patients don't know about available trials

**Why patients don't enroll in trials**:

1. **Don't know trials exist**: Trials are advertised on ClinicalTrials.gov (confusing, technical), not patient-friendly platforms
2. **Don't know if they're eligible**: Complex eligibility criteria (FEV1 ranges, genotype, medication history), patients can't self-assess
3. **Geographic barriers**: Trials at specialized centers (Cleveland, Denver, Portland), patients 1,000+ miles away
4. **Fear and mistrust**: "Am I a guinea pig?" "What if I get the placebo?" "Will it hurt me?"
5. **No incentive**: Trials require time (travel, appointments), financial burden, no compensation

**Why researchers struggle to recruit**:

1. **Fragmented patient population**: 10,000 diagnosed patients spread across 50 states, no centralized contact method
2. **No searchable registry**: Patient Registry exists but isn't connected to trial recruitment
3. **Referral bottlenecks**: Researchers rely on physicians to refer patients (slow, inconsistent)
4. **Screening failures**: 50% of enrolled patients fail screening (wasted time, money)

**The opportunity**:

- **Alpha1Life has 8,000+ registered patients** (80% of diagnosed population)
- **90% consent to be contacted for research** (Patient Registry survey)
- **Match rate potential**: If we automated trial matching, we could triple enrollment (5% â†’ 15%)

**What patients need**:

1. **Trial discovery**: "Show me trials I'm eligible for" (based on my FEV1, genotype, location)
2. **Plain-language explanations**: "What will this trial involve? How many visits? What are the risks?"
3. **Logistical support**: Travel grants, lodging assistance, visit scheduling
4. **Peer stories**: "I enrolled in a trial and it changed my life" (testimonials)

**What researchers need**:

1. **Patient pool access**: "Show me all PI\*ZZ patients with FEV1 35-60% in the Midwest"
2. **Pre-screening**: "Which patients meet my eligibility criteria?" (before outreach)
3. **Consent management**: HIPAA-compliant opt-in/opt-out, audit trail
4. **Recruitment analytics**: "How many patients viewed my trial? How many enrolled?"

### The Solution

Build a **Research Participation & Clinical Trial Matching Platform** that provides:

1. **Trial Matching Engine**: Automated matching based on Patient Registry data (genotype, FEV1, location, medications, comorbidities)
2. **Patient-Facing Trial Portal**: Search trials, get matched, learn about research participation
3. **Researcher Dashboard**: Search patient pool, send targeted recruitment messages, track enrollment
4. **Eligibility Pre-Screening**: Automated checks (80% of eligibility criteria can be automated), flag likely matches
5. **Consent Management**: Granular consent (opt into all research, specific trials only, withdraw anytime)
6. **Travel Grants Program**: MEF funds travel/lodging for trial participants ($500-$1,500/patient)
7. **Research Education Hub**: "Why participate in research?" Videos, FAQs, patient testimonials
8. **ClinicalTrials.gov Integration**: Automatically ingest Alpha-1 trials, update status, display on Alpha1Life

### Impact

**Year 1 Targets**:

- **500 patients matched to trials** (from current 200/year = 2.5x increase)
- **200 patients enrolled in trials** (from current 80/year = 2.5x increase)
- **15% enrollment rate** (from current 5%, triple the conversion)
- **20 active Alpha-1 trials** listed on platform (all major U.S. trials)
- **50 travel grants awarded** ($500-$1,500 each, remove financial barriers)

**Long-Term Impact** (5 Years):

- **2,000 patients enrolled in trials** (cumulative, 25% of diagnosed population)
- **Faster trial completion**: Recruitment time reduced 50% (24 months â†’ 12 months)
- **More trials launched**: Sponsors confident in recruitment â†’ more Alpha-1 trials funded
- **Breakthrough treatments**: Gene therapy, next-gen augmentation approved faster
- **Research funding increase**: NIH sees engagement â†’ increases Alpha-1 funding

---

## ğŸ’° Business Case

### Investment Required

**One-Time Development**: $95,000 - $140,000

- Trial matching engine: $30K-$45K (eligibility algorithm, automated pre-screening)
- Patient portal: $20K-$30K (trial search, profile-based matching)
- Researcher dashboard: $20K-$30K (patient pool search, messaging, analytics)
- ClinicalTrials.gov API integration: $10K-$15K (automated trial ingestion)
- Consent management system: $8K-$12K (granular opt-in/opt-out, HIPAA compliance)
- Research education hub: $5K-$8K (videos, FAQs, patient stories)
- Contingency (15%): $14K-$21K

**Annual Operating**: $120,000 - $180,000

- Research coordinator: $60K-$90K/year (full-time, manage trial matching, patient outreach)
- Travel grants program: $30K-$50K/year (50-80 grants @ $500-$1,500 each)
- Platform maintenance: $8K-$12K/year (updates, bug fixes)
- ClinicalTrials.gov monitoring: $5K-$8K/year (check for new Alpha-1 trials weekly)
- Consent management/compliance: $5K-$8K/year (annual HIPAA audit, legal review)
- Patient education materials: $5K-$8K/year (update videos, print materials)
- IRB/ethics consultation: $7K-$10K/year (ensure recruitment practices are ethical)

**Total 3-Year Cost**: $455K-$680K (one-time dev + 3 years operating)

### Revenue Potential

**Researcher Access Fees** (Controversial, must balance access with mission):

- **Free for academic researchers** (universities, non-profits)
- **Paid for pharma sponsors**: $10K-$25K/year per trial (access to patient pool, recruitment support)
  - Year 1: 5 pharma trials Ã— $15K avg = $75,000
  - Year 2: 8 pharma trials Ã— $18K avg = $144,000
  - Year 3: 10 pharma trials Ã— $20K avg = $200,000

**Grant Funding**:

- **NIH/PCORI grants**: $100K-$200K/year (research infrastructure grants)
  - Year 1: $100,000
  - Year 2: $150,000
  - Year 3: $200,000

**Pharma Sponsorships** (Unrestricted grants):

- Grifols, CSL Behring, Takeda support patient recruitment infrastructure
  - Year 1: $50,000
  - Year 2: $75,000
  - Year 3: $100,000

**Total 3-Year Revenue**: $1,094,000

**Net 3-Year Impact**: +$414K to +$639K (91-140% ROI)

**Intangible Value**:

- **Accelerated research**: Trials complete faster â†’ treatments approved sooner (priceless)
- **Patient access to cutting-edge therapies**: Trial participants get experimental treatments years before FDA approval
- **Increased NIH funding**: Demonstrate infrastructure â†’ NIH invests more in Alpha-1 research
- **Pharma interest**: Show strong recruitment â†’ more companies develop Alpha-1 drugs

---

## ğŸ¯ Market Opportunity

### Target Audience

**Primary Users**:

1. **Alpha-1 Patients** (10,000 diagnosed in U.S.)
   - Want to contribute to research, help future patients
   - Need: Easy way to find trials they qualify for
   - **Target Year 1**: 500 matched to trials (5% of diagnosed)

2. **Researchers** (Academic & Pharma)
   - Academic: 50-100 principal investigators studying Alpha-1 in U.S.
   - Pharma: Grifols, CSL Behring, Takeda, gene therapy companies (Vertex, Arrowhead)
   - Need: Access to patient pool, efficient recruitment

**Secondary Users**:

- Healthcare providers (refer patients to trials)
- Genetic counselors (educate families about research participation)
- Patient advocacy organizations (promote trial awareness)

### Market Size

**U.S. Alpha-1 Patients**: 10,000 diagnosed, 8,000 in Alpha1Life Registry
**Trial Participation Interest**: 90% (7,200 patients willing)
**Current Enrollment**: 5% (400 patients/year across all trials)
**Target Enrollment**: 15% (1,200 patients/year = 3x increase)

**Active Alpha-1 Trials**: 20-30/year in U.S. (per ClinicalTrials.gov)
**Recruitment Challenges**: 80% of trials report recruitment as #1 bottleneck

### Competitive Landscape

**Existing Solutions**:

1. **ClinicalTrials.gov** (NIH):
   - Government trial registry, 400K+ trials
   - **Gap**: Technical language, not patient-friendly, no automated matching

2. **Alpha-1 Foundation Trial Listings**:
   - Basic list of trials (PDF on website)
   - **Gap**: No matching, no eligibility screening, no enrollment support

3. **Pharma Direct Recruitment**:
   - Grifols, CSL Behring recruit via email blasts to their patient databases
   - **Gap**: Only their own trials, no multi-sponsor platform

4. **Generic Trial Matching Services** (TrialX, Antidote):
   - Match patients to trials across all diseases
   - **Gap**: Not Alpha-1 specific, miss nuances (genotype, FEV1 ranges)

**Alpha1Life Advantage**:

- âœ… Alpha-1 specific (understands disease nuances)
- âœ… Largest patient pool (8,000 registered patients, 80% of diagnosed)
- âœ… Rich data (Patient Registry has genotype, FEV1, medications, comorbidities)
- âœ… Automated pre-screening (reduce screening failures 50%)
- âœ… Logistical support (travel grants, visit coordination)
- âœ… Trusted source (patients trust MEF more than pharma)

---

## âœ¨ Core Features

### 1. Patient-Facing Trial Portal

**Dashboard**:

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ”¬ Your Clinical Trial Matches                  â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ Based on your Patient Registry profile, we foundâ”‚
â”‚ 3 trials you may be eligible for.               â”‚
â”‚                                                 â”‚
â”‚ â­ HIGHLY RECOMMENDED MATCH (95% fit)           â”‚
â”‚                                                 â”‚
â”‚ Gene Therapy Trial for Alpha-1                  â”‚
â”‚ Sponsor: Arrowhead Pharmaceuticals              â”‚
â”‚ Phase: Phase 2 (early-stage, testing safety)    â”‚
â”‚ Location: National Jewish Health, Denver, CO    â”‚
â”‚ Distance from you: 380 miles                    â”‚
â”‚                                                 â”‚
â”‚ Why you're a match:                             â”‚
â”‚ âœ“ Genotype: PI*ZZ (required)                    â”‚
â”‚ âœ“ FEV1: 52% (trial needs 35-65%)                â”‚
â”‚ âœ“ Age: 42 (trial needs 18-65)                   â”‚
â”‚ âœ“ Not on augmentation therapy (required)        â”‚
â”‚ âœ“ No liver disease (required)                   â”‚
â”‚                                                 â”‚
â”‚ What this trial involves:                       â”‚
â”‚ â€¢ Treatment: Single infusion of experimental geneâ”‚
â”‚   therapy (AATM-001) + monitoring               â”‚
â”‚ â€¢ Visits: 15 visits over 24 months (Months 0, 1,â”‚
â”‚   3, 6, 9, 12, 15, 18, 21, 24)                  â”‚
â”‚ â€¢ Time commitment: ~100 hours total             â”‚
â”‚ â€¢ Compensation: Travel/lodging reimbursed up to  â”‚
â”‚   $2,000, $50 gift card per visit               â”‚
â”‚ â€¢ Risks: Infusion reactions (rare), unknown     â”‚
â”‚   long-term effects                             â”‚
â”‚ â€¢ Benefits: May increase AAT levels, slow diseaseâ”‚
â”‚   progression (experimental, not guaranteed)    â”‚
â”‚                                                 â”‚
â”‚ [ğŸ“– Learn More] [âœ… Express Interest] [âŒ Not   â”‚
â”‚ Interested]                                     â”‚
â”‚                                                 â”‚
â”‚ â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€  â”‚
â”‚                                                 â”‚
â”‚ GOOD MATCH (78% fit)                            â”‚
â”‚                                                 â”‚
â”‚ Augmentation Therapy Comparison Study           â”‚
â”‚ Sponsor: Grifols                                â”‚
â”‚ Phase: Phase 3b (comparing two doses)           â”‚
â”‚ Location: Cleveland Clinic, Cleveland, OH       â”‚
â”‚ Distance from you: 140 miles                    â”‚
â”‚                                                 â”‚
â”‚ Why you're a match:                             â”‚
â”‚ âœ“ Genotype: PI*ZZ (required)                    â”‚
â”‚ âœ“ FEV1: 52% (trial needs 35-65%)                â”‚
â”‚ âš  Already on Prolastin (trial prefers naive, butâ”‚
â”‚   may allow if you switch)                      â”‚
â”‚                                                 â”‚
â”‚ [ğŸ“– Learn More] [âœ… Express Interest]           â”‚
â”‚                                                 â”‚
â”‚ â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€  â”‚
â”‚                                                 â”‚
â”‚ POSSIBLE MATCH (65% fit)                        â”‚
â”‚                                                 â”‚
â”‚ Exercise & Nutrition Intervention Study         â”‚
â”‚ Sponsor: University of Florida                  â”‚
â”‚ Phase: Observational (no experimental drugs)    â”‚
â”‚ Location: Virtual (telehealth visits)           â”‚
â”‚                                                 â”‚
â”‚ Why you're a match:                             â”‚
â”‚ âœ“ Genotype: PI*ZZ (required)                    â”‚
â”‚ âœ“ FEV1: 52% (trial needs 40-80%)                â”‚
â”‚ âš  Must commit to 6-month exercise program       â”‚
â”‚                                                 â”‚
â”‚ [ğŸ“– Learn More] [âœ… Express Interest]           â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**Trial Detail Page**:

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ”¬ TRIAL DETAILS                                â”‚
â”‚ Gene Therapy Trial for Alpha-1 (AATM-001)       â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ PLAIN-LANGUAGE SUMMARY:                         â”‚
â”‚ This trial is testing a new gene therapy that   â”‚
â”‚ aims to "fix" the genetic defect causing Alpha-1.â”‚
â”‚ You'll receive a single infusion of the          â”‚
â”‚ experimental treatment, then be monitored for 2  â”‚
â”‚ years to see if your AAT levels increase and     â”‚
â”‚ your lung function stabilizes.                   â”‚
â”‚                                                 â”‚
â”‚ WHO CAN PARTICIPATE:                            â”‚
â”‚ âœ“ PI*ZZ genotype                                â”‚
â”‚ âœ“ Age 18-65                                     â”‚
â”‚ âœ“ FEV1 35-65% predicted                         â”‚
â”‚ âœ“ Not currently on augmentation therapy         â”‚
â”‚ âœ“ No liver cirrhosis                            â”‚
â”‚ âœ“ Willing to travel to Denver 15 times over 2   â”‚
â”‚   years                                         â”‚
â”‚                                                 â”‚
â”‚ YOUR ELIGIBILITY:                               â”‚
â”‚ âœ… You meet all major criteria!                 â”‚
â”‚ âš ï¸ Final eligibility confirmed by study team    â”‚
â”‚    (blood tests, imaging, medical history review)â”‚
â”‚                                                 â”‚
â”‚ WHAT TO EXPECT:                                 â”‚
â”‚ Week 1: Screening visit (4 hours, blood tests,  â”‚
â”‚         PFTs, CT scan)                          â”‚
â”‚ Week 2: Infusion visit (8 hours, IV infusion of â”‚
â”‚         gene therapy + 4-hour observation)      â”‚
â”‚ Months 1-24: Follow-up visits (2 hours each,    â”‚
â”‚         blood tests, PFTs, safety monitoring)   â”‚
â”‚                                                 â”‚
â”‚ RISKS:                                          â”‚
â”‚ â€¢ Common: Infusion reactions (fever, chills),   â”‚
â”‚   bruising at IV site                           â”‚
â”‚ â€¢ Rare: Severe allergic reaction, liver enzyme  â”‚
â”‚   elevation                                     â”‚
â”‚ â€¢ Unknown: Long-term effects of gene therapy    â”‚
â”‚   (this is experimental)                        â”‚
â”‚                                                 â”‚
â”‚ BENEFITS:                                       â”‚
â”‚ â€¢ Potential: Increase AAT levels, slow lung     â”‚
â”‚   decline                                       â”‚
â”‚ â€¢ You'll help advance research (benefit future  â”‚
â”‚   patients even if it doesn't help you)         â”‚
â”‚ â€¢ Free AAT levels, PFTs, CT scans (worth $5K+)  â”‚
â”‚ â€¢ Travel reimbursement + $750 total compensationâ”‚
â”‚                                                 â”‚
â”‚ PATIENT TESTIMONIALS:                           â”‚
â”‚ ğŸ’¬ "I enrolled in this trial 18 months ago. My  â”‚
â”‚     AAT levels tripled! My FEV1 is stable. I'm  â”‚
â”‚     so glad I did this." - Mark, 45, PI*ZZ      â”‚
â”‚                                                 â”‚
â”‚ ğŸ’¬ "The study team was amazing. Travel was      â”‚
â”‚     reimbursed. I feel like I'm contributing to â”‚
â”‚     finding a cure." - Linda, 52, PI*ZZ         â”‚
â”‚                                                 â”‚
â”‚ CONTACT STUDY TEAM:                             â”‚
â”‚ Principal Investigator: Dr. Emily Roberts       â”‚
â”‚ Study Coordinator: Sarah Johnson, RN            â”‚
â”‚ Phone: (303) 555-1234                           â”‚
â”‚ Email: alpha1trial@njhealth.org                 â”‚
â”‚                                                 â”‚
â”‚ [âœ… Express Interest] [ğŸ“§ Ask Questions]        â”‚
â”‚ [ğŸ“„ View Full Protocol (Technical)]             â”‚
â”‚                                                 â”‚
â”‚ TRAVEL GRANT AVAILABLE:                         â”‚
â”‚ Mark Egly Foundation offers up to $1,500 to     â”‚
â”‚ cover travel/lodging for trial participants.    â”‚
â”‚ [ğŸ“‹ Apply for Travel Grant]                     â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

### 2. Researcher Dashboard

**Patient Pool Search**:

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ‘¨â€ğŸ”¬ Researcher Dashboard: Patient Pool Search    â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ Search the Alpha1Life Patient Registry for      â”‚
â”‚ potential trial participants.                   â”‚
â”‚                                                 â”‚
â”‚ TRIAL: Gene Therapy Study (AATM-001)            â”‚
â”‚ PI: Dr. Emily Roberts, National Jewish Health   â”‚
â”‚                                                 â”‚
â”‚ DEFINE ELIGIBILITY CRITERIA:                    â”‚
â”‚                                                 â”‚
â”‚ Genotype:                                       â”‚
â”‚ â˜‘ PI*ZZ  â˜ PI*SZ  â˜ PI*MZ  â˜ Other              â”‚
â”‚                                                 â”‚
â”‚ Lung Function (FEV1):                           â”‚
â”‚ Min: [35]%  Max: [65]%                          â”‚
â”‚                                                 â”‚
â”‚ Age:                                            â”‚
â”‚ Min: [18]  Max: [65]                            â”‚
â”‚                                                 â”‚
â”‚ Current Medications:                            â”‚
â”‚ â˜‘ NOT on augmentation therapy (exclusion)       â”‚
â”‚ â˜ On oxygen (optional inclusion/exclusion)      â”‚
â”‚                                                 â”‚
â”‚ Comorbidities (Exclusions):                     â”‚
â”‚ â˜‘ No liver cirrhosis                            â”‚
â”‚ â˜‘ No active cancer                              â”‚
â”‚ â˜‘ No pregnancy (women)                          â”‚
â”‚                                                 â”‚
â”‚ Geographic Preference:                          â”‚
â”‚ Trial site: Denver, CO                          â”‚
â”‚ â˜‘ Within 500 miles  â˜ Any location              â”‚
â”‚                                                 â”‚
â”‚ [ğŸ” Search Patient Pool]                        â”‚
â”‚                                                 â”‚
â”‚ â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€  â”‚
â”‚                                                 â”‚
â”‚ SEARCH RESULTS: 127 Potential Matches           â”‚
â”‚                                                 â”‚
â”‚ MATCH QUALITY BREAKDOWN:                        â”‚
â”‚ â€¢ Highly Likely (90-100% match): 42 patients    â”‚
â”‚ â€¢ Likely (75-89% match): 58 patients            â”‚
â”‚ â€¢ Possible (60-74% match): 27 patients          â”‚
â”‚                                                 â”‚
â”‚ GEOGRAPHIC DISTRIBUTION:                        â”‚
â”‚ â€¢ Colorado: 8 patients (same state)             â”‚
â”‚ â€¢ Wyoming: 12 patients (<300 mi)                â”‚
â”‚ â€¢ Nebraska: 15 patients (<400 mi)               â”‚
â”‚ â€¢ Kansas: 18 patients (<500 mi)                 â”‚
â”‚ â€¢ Other states: 74 patients (>500 mi)           â”‚
â”‚                                                 â”‚
â”‚ NEXT STEPS:                                     â”‚
â”‚ 1. Review individual patient profiles (de-      â”‚
â”‚    identified until consent)                    â”‚
â”‚ 2. Send recruitment message to selected patientsâ”‚
â”‚ 3. Track responses and enrollment               â”‚
â”‚                                                 â”‚
â”‚ [ğŸ“Š View Detailed Results] [ğŸ“§ Send Recruitment â”‚
â”‚ Message]                                        â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**Recruitment Message Tool**:

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ“§ Send Recruitment Message                     â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ RECIPIENTS: 42 patients (Highly Likely matches) â”‚
â”‚                                                 â”‚
â”‚ MESSAGE TEMPLATE:                               â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â” â”‚
â”‚ â”‚ Subject: You May Qualify for an Alpha-1  â”‚ â”‚
â”‚ â”‚ Gene Therapy Trial                        â”‚ â”‚
â”‚ â”‚                                           â”‚ â”‚
â”‚ â”‚ Dear [First Name],                        â”‚ â”‚
â”‚ â”‚                                           â”‚ â”‚
â”‚ â”‚ Based on your Patient Registry profile,  â”‚ â”‚
â”‚ â”‚ you may qualify for a new gene therapy   â”‚ â”‚
â”‚ â”‚ trial at National Jewish Health in Denver.â”‚ â”‚
â”‚ â”‚                                           â”‚ â”‚
â”‚ â”‚ This study is testing AATM-001, an        â”‚ â”‚
â”‚ â”‚ experimental treatment that aims to       â”‚ â”‚
â”‚ â”‚ increase your body's production of alpha-1â”‚ â”‚
â”‚ â”‚ antitrypsin.                              â”‚ â”‚
â”‚ â”‚                                           â”‚ â”‚
â”‚ â”‚ Eligibility:                              â”‚ â”‚
â”‚ â”‚ â€¢ PI*ZZ genotype                          â”‚ â”‚
â”‚ â”‚ â€¢ FEV1 35-65%                             â”‚ â”‚
â”‚ â”‚ â€¢ Not on augmentation therapy             â”‚ â”‚
â”‚ â”‚                                           â”‚ â”‚
â”‚ â”‚ Participation involves 15 visits over 2   â”‚ â”‚
â”‚ â”‚ years. Travel/lodging reimbursed up to    â”‚ â”‚
â”‚ â”‚ $2,000. MEF travel grants also available. â”‚ â”‚
â”‚ â”‚                                           â”‚ â”‚
â”‚ â”‚ Learn more: [LINK]                        â”‚ â”‚
â”‚ â”‚ Express interest: [LINK]                  â”‚ â”‚
â”‚ â”‚                                           â”‚ â”‚
â”‚ â”‚ Questions? Contact study coordinator:     â”‚ â”‚
â”‚ â”‚ Sarah Johnson, RN - (303) 555-1234        â”‚ â”‚
â”‚ â”‚                                           â”‚ â”‚
â”‚ â”‚ Thank you for considering research        â”‚ â”‚
â”‚ â”‚ participation!                            â”‚ â”‚
â”‚ â”‚                                           â”‚ â”‚
â”‚ â”‚ Dr. Emily Roberts, Principal Investigator â”‚ â”‚
â”‚ â”‚ National Jewish Health                    â”‚ â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜ â”‚
â”‚                                                 â”‚
â”‚ COMPLIANCE CHECK:                               â”‚
â”‚ âœ… IRB-approved language                        â”‚
â”‚ âœ… Opt-out link included                        â”‚
â”‚ âœ… Privacy policy referenced                    â”‚
â”‚ âœ… No coercive language                         â”‚
â”‚                                                 â”‚
â”‚ [ğŸ“§ Send to 42 Patients] [ğŸ’¾ Save Draft]        â”‚
â”‚ [ğŸ‘ï¸ Preview Email]                             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**Recruitment Analytics**:

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ“Š Trial Recruitment Analytics                  â”‚
â”‚ Gene Therapy Study (AATM-001)                   â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ CAMPAIGN PERFORMANCE:                           â”‚
â”‚                                                 â”‚
â”‚ Messages sent: 127                              â”‚
â”‚ Opened: 98 (77%)                                â”‚
â”‚ Clicked "Learn More": 62 (49%)                  â”‚
â”‚ Expressed interest: 31 (24%)                    â”‚
â”‚ Scheduled screening: 18 (14%)                   â”‚
â”‚ Enrolled: 12 (9%)                               â”‚
â”‚ Failed screening: 6 (3%)                        â”‚
â”‚                                                 â”‚
â”‚ FUNNEL VISUALIZATION:                           â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”‚
â”‚ â”‚ 127 Contacted                           â”‚   â”‚
â”‚ â”‚ â–¼ 77% open rate                         â”‚   â”‚
â”‚ â”‚ 98 Opened                               â”‚   â”‚
â”‚ â”‚ â–¼ 63% click rate                        â”‚   â”‚
â”‚ â”‚ 62 Clicked                              â”‚   â”‚
â”‚ â”‚ â–¼ 50% interest rate                     â”‚   â”‚
â”‚ â”‚ 31 Expressed Interest                   â”‚   â”‚
â”‚ â”‚ â–¼ 58% screening rate                    â”‚   â”‚
â”‚ â”‚ 18 Scheduled Screening                  â”‚   â”‚
â”‚ â”‚ â–¼ 67% enrollment rate                   â”‚   â”‚
â”‚ â”‚ 12 Enrolled âœ“                           â”‚   â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â”‚
â”‚                                                 â”‚
â”‚ ENROLLMENT GOAL: 50 patients                    â”‚
â”‚ Current: 12 (24%)                               â”‚
â”‚ On track: YES (ahead of schedule)               â”‚
â”‚                                                 â”‚
â”‚ TIME TO ENROLLMENT:                             â”‚
â”‚ Average: 18 days (from first contact to consent)â”‚
â”‚ Industry average: 45 days (60% faster!)         â”‚
â”‚                                                 â”‚
â”‚ PATIENT FEEDBACK (Post-Enrollment Survey):      â”‚
â”‚ "How did you hear about this trial?"            â”‚
â”‚ â€¢ Alpha1Life email: 10 (83%)                    â”‚
â”‚ â€¢ Doctor referral: 2 (17%)                      â”‚
â”‚                                                 â”‚
â”‚ "What convinced you to enroll?"                 â”‚
â”‚ â€¢ Trust in Alpha1Life: 8 (67%)                  â”‚
â”‚ â€¢ Plain-language explanation: 6 (50%)           â”‚
â”‚ â€¢ Travel grant availability: 4 (33%)            â”‚
â”‚                                                 â”‚
â”‚ [ğŸ“¥ Export Report] [ğŸ“§ Request More Patients]   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

### 3. Automated Eligibility Pre-Screening

**Matching Algorithm**:

```javascript
// Node.js - Calculate trial eligibility score
function calculateEligibility(patient, trial) {
  let score = 0;
  let maxScore = 0;
  let criteria = [];

  // Genotype (critical, 30 points)
  maxScore += 30;
  if (trial.genotype_required.includes(patient.genotype)) {
    score += 30;
    criteria.push({ criterion: 'Genotype', met: true, weight: 'critical' });
  } else {
    criteria.push({ criterion: 'Genotype', met: false, weight: 'critical' });
  }

  // FEV1 (critical, 25 points)
  maxScore += 25;
  if (
    patient.fev1_percent >= trial.fev1_min &&
    patient.fev1_percent <= trial.fev1_max
  ) {
    score += 25;
    criteria.push({ criterion: 'FEV1', met: true, weight: 'critical' });
  } else {
    criteria.push({ criterion: 'FEV1', met: false, weight: 'critical' });
  }

  // Age (critical, 20 points)
  maxScore += 20;
  if (patient.age >= trial.age_min && patient.age <= trial.age_max) {
    score += 20;
    criteria.push({ criterion: 'Age', met: true, weight: 'critical' });
  } else {
    criteria.push({ criterion: 'Age', met: false, weight: 'critical' });
  }

  // Augmentation therapy status (major, 15 points)
  maxScore += 15;
  if (trial.augmentation_required === 'none' && !patient.on_augmentation) {
    score += 15;
    criteria.push({
      criterion: 'Not on augmentation',
      met: true,
      weight: 'major'
    });
  } else if (trial.augmentation_required === 'yes' && patient.on_augmentation) {
    score += 15;
    criteria.push({ criterion: 'On augmentation', met: true, weight: 'major' });
  } else if (trial.augmentation_required === 'any') {
    score += 15;
    criteria.push({
      criterion: 'Augmentation status',
      met: true,
      weight: 'major'
    });
  } else {
    criteria.push({
      criterion: 'Augmentation status',
      met: false,
      weight: 'major'
    });
  }

  // Liver disease (exclusion, 10 points)
  maxScore += 10;
  if (!trial.exclude_liver_disease || !patient.liver_cirrhosis) {
    score += 10;
    criteria.push({
      criterion: 'No liver cirrhosis',
      met: true,
      weight: 'minor'
    });
  } else {
    criteria.push({
      criterion: 'No liver cirrhosis',
      met: false,
      weight: 'minor'
    });
  }

  // Geographic proximity (minor, 10 points)
  maxScore += 10;
  const distance = calculateDistance(patient.zip_code, trial.site_zip_code);
  if (distance <= 200) score += 10;
  else if (distance <= 500) score += 7;
  else if (distance <= 1000) score += 4;
  criteria.push({
    criterion: `Distance from trial site: ${distance} mi`,
    met: distance <= 500,
    weight: 'minor'
  });

  const eligibilityPercent = Math.round((score / maxScore) * 100);

  return {
    score: eligibilityPercent,
    category:
      eligibilityPercent >= 90
        ? 'highly_likely'
        : eligibilityPercent >= 75
          ? 'likely'
          : eligibilityPercent >= 60
            ? 'possible'
            : 'unlikely',
    criteria: criteria
  };
}
```

---

### 4. Travel Grants Program

**Application Process**:

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ âœˆï¸ MEF Clinical Trial Travel Grant              â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ The Mark Egly Foundation provides travel grants â”‚
â”‚ to help Alpha-1 patients participate in clinicalâ”‚
â”‚ trials.                                         â”‚
â”‚                                                 â”‚
â”‚ ELIGIBILITY:                                    â”‚
â”‚ â€¢ Enrolled in an Alpha-1 clinical trial         â”‚
â”‚ â€¢ Trial site is 100+ miles from your home       â”‚
â”‚ â€¢ Financial need (household income <$100K or    â”‚
â”‚   significant hardship)                         â”‚
â”‚                                                 â”‚
â”‚ GRANT AMOUNTS:                                  â”‚
â”‚ â€¢ 100-300 miles: Up to $500/visit               â”‚
â”‚ â€¢ 300-800 miles: Up to $1,000/visit             â”‚
â”‚ â€¢ 800+ miles: Up to $1,500/visit                â”‚
â”‚                                                 â”‚
â”‚ COVERED EXPENSES:                               â”‚
â”‚ âœ… Airfare or mileage reimbursement             â”‚
â”‚ âœ… Hotel (up to $150/night, 2 nights max)       â”‚
â”‚ âœ… Meals (up to $50/day)                        â”‚
â”‚ âœ… Parking/tolls                                â”‚
â”‚ âŒ Not covered: Non-trial medical expenses,     â”‚
â”‚    personal shopping, entertainment             â”‚
â”‚                                                 â”‚
â”‚ APPLICATION (5 minutes):                        â”‚
â”‚                                                 â”‚
â”‚ Trial you're enrolled in:                       â”‚
â”‚ [Gene Therapy Study (AATM-001) â–¼]               â”‚
â”‚                                                 â”‚
â”‚ Trial site:                                     â”‚
â”‚ [National Jewish Health, Denver, CO]            â”‚
â”‚                                                 â”‚
â”‚ Your home address:                              â”‚
â”‚ [Columbus, OH] (Distance: 1,260 miles)          â”‚
â”‚                                                 â”‚
â”‚ Visit dates you need funding for:               â”‚
â”‚ â˜‘ Screening visit (Dec 15, 2025)                â”‚
â”‚ â˜‘ Infusion visit (Jan 10, 2026)                 â”‚
â”‚ â˜ Month 1 follow-up (Feb 10, 2026)              â”‚
â”‚                                                 â”‚
â”‚ Estimated expenses:                             â”‚
â”‚ â€¢ Airfare (roundtrip): $450                     â”‚
â”‚ â€¢ Hotel (2 nights): $300                        â”‚
â”‚ â€¢ Meals: $100                                   â”‚
â”‚ â€¢ Airport parking: $50                          â”‚
â”‚ Total: $900                                     â”‚
â”‚                                                 â”‚
â”‚ Grant amount requested: [$900]                  â”‚
â”‚                                                 â”‚
â”‚ Brief explanation of financial need:            â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”‚
â”‚ â”‚ I'm on disability due to Alpha-1. My    â”‚   â”‚
â”‚ â”‚ income is $2,400/month. This trial couldâ”‚   â”‚
â”‚ â”‚ help me, but I can't afford the travel. â”‚   â”‚
â”‚ â”‚ This grant would make it possible.      â”‚   â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â”‚
â”‚                                                 â”‚
â”‚ [ğŸ“¤ Submit Application]                         â”‚
â”‚                                                 â”‚
â”‚ Applications reviewed within 5 business days.   â”‚
â”‚ Approved grants paid directly to you via check  â”‚
â”‚ or direct deposit.                              â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

### 5. Research Education Hub

**"Why Participate in Research?" Video Series**:

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ¥ Research Education Hub                       â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ VIDEO 1: "What is a Clinical Trial?" (5 min)   â”‚
â”‚ â€¢ Phases explained (1, 2, 3, 4)                 â”‚
â”‚ â€¢ Placebo vs. active treatment                  â”‚
â”‚ â€¢ Risks vs. benefits                            â”‚
â”‚ [â–¶ï¸ Watch] [ğŸ“„ Transcript]                      â”‚
â”‚                                                 â”‚
â”‚ VIDEO 2: "Your Rights as a Research             â”‚
â”‚ Participant" (4 min)                            â”‚
â”‚ â€¢ Informed consent process                      â”‚
â”‚ â€¢ You can withdraw anytime                      â”‚
â”‚ â€¢ Privacy protections (HIPAA)                   â”‚
â”‚ [â–¶ï¸ Watch]                                      â”‚
â”‚                                                 â”‚
â”‚ VIDEO 3: "Patient Stories: I Enrolled in a      â”‚
â”‚ Trial" (8 min)                                  â”‚
â”‚ â€¢ Mark, 45: "Gene therapy changed my life"      â”‚
â”‚ â€¢ Linda, 52: "I did it for my grandkids"        â”‚
â”‚ â€¢ Tom, 60: "Best decision I ever made"          â”‚
â”‚ [â–¶ï¸ Watch]                                      â”‚
â”‚                                                 â”‚
â”‚ VIDEO 4: "How Trials Lead to New Treatments"    â”‚
â”‚ (6 min)                                         â”‚
â”‚ â€¢ Augmentation therapy history (trials â†’ FDA    â”‚
â”‚   approval)                                     â”‚
â”‚ â€¢ Gene therapy pipeline (what's coming)         â”‚
â”‚ [â–¶ï¸ Watch]                                      â”‚
â”‚                                                 â”‚
â”‚ FAQS:                                           â”‚
â”‚ â€¢ Will I get a placebo? (Depends on trial)      â”‚
â”‚ â€¢ What if I have side effects? (Report to study â”‚
â”‚   team, they'll help)                           â”‚
â”‚ â€¢ Will my insurance cover trial costs? (Yes,    â”‚
â”‚   standard care covered; experimental drug free)â”‚
â”‚ â€¢ What if the trial doesn't help me? (You still â”‚
â”‚   helped future patients)                       â”‚
â”‚ [ğŸ“– Read All FAQs]                              â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

## ğŸ”§ Technical Implementation

### Architecture

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ Alpha1Life.com Platform                         â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”‚
â”‚ â”‚ Clinical Trial Matching Plugin          â”‚   â”‚
â”‚ â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â” â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”‚   â”‚
â”‚ â”‚ â”‚ Trial        â”‚ â”‚ Eligibility      â”‚   â”‚   â”‚
â”‚ â”‚ â”‚ Database     â”‚ â”‚ Algorithm        â”‚   â”‚   â”‚
â”‚ â”‚ â”‚ (Ingested    â”‚ â”‚ (Automated       â”‚   â”‚   â”‚
â”‚ â”‚ â”‚  from CT.gov)â”‚ â”‚  Pre-Screening)  â”‚   â”‚   â”‚
â”‚ â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â”‚   â”‚
â”‚ â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â” â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”‚   â”‚
â”‚ â”‚ â”‚ Patient      â”‚ â”‚ Researcher       â”‚   â”‚   â”‚
â”‚ â”‚ â”‚ Portal       â”‚ â”‚ Dashboard        â”‚   â”‚   â”‚
â”‚ â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â”‚   â”‚
â”‚ â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â” â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”‚   â”‚
â”‚ â”‚ â”‚ Consent      â”‚ â”‚ Travel Grants    â”‚   â”‚   â”‚
â”‚ â”‚ â”‚ Management   â”‚ â”‚ Application      â”‚   â”‚   â”‚
â”‚ â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â”‚   â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
          â†“                           â†“
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”       â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ClinicalTrials   â”‚       â”‚ Patient Registry     â”‚
â”‚ .gov API         â”‚       â”‚ (Genotype, FEV1,     â”‚
â”‚ (Trial ingestion)â”‚       â”‚  Medications, etc.)  â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜       â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### Database Schema

```sql
-- Clinical Trials
CREATE TABLE clinical_trials (
  id SERIAL PRIMARY KEY,
  nct_id VARCHAR(20) UNIQUE, -- ClinicalTrials.gov NCT number
  title VARCHAR(500),
  sponsor VARCHAR(200),
  phase VARCHAR(20), -- "Phase 1", "Phase 2", "Phase 3", "Phase 4"
  status VARCHAR(50), -- "Recruiting", "Active, not recruiting", "Completed"
  description TEXT,
  eligibility_criteria TEXT, -- Full eligibility (free-text)
  start_date DATE,
  completion_date DATE,
  primary_outcome TEXT,
  last_updated TIMESTAMP,
  created_at TIMESTAMP DEFAULT NOW()
);

-- Trial Sites
CREATE TABLE trial_sites (
  id SERIAL PRIMARY KEY,
  trial_id INTEGER REFERENCES clinical_trials(id),
  facility_name VARCHAR(200),
  city VARCHAR(100),
  state VARCHAR(2),
  zip_code VARCHAR(10),
  country VARCHAR(50) DEFAULT 'USA',
  contact_name VARCHAR(200),
  contact_phone VARCHAR(20),
  contact_email VARCHAR(200),
  created_at TIMESTAMP DEFAULT NOW()
);

-- Structured Eligibility Criteria (for automated matching)
CREATE TABLE trial_eligibility (
  id SERIAL PRIMARY KEY,
  trial_id INTEGER REFERENCES clinical_trials(id),
  genotype_required VARCHAR(50)[], -- ["PI*ZZ", "PI*SZ"]
  fev1_min INTEGER, -- Minimum FEV1 % predicted
  fev1_max INTEGER,
  age_min INTEGER,
  age_max INTEGER,
  augmentation_required VARCHAR(20), -- "yes", "no", "any"
  oxygen_allowed BOOLEAN DEFAULT TRUE,
  liver_cirrhosis_exclusion BOOLEAN DEFAULT FALSE,
  pregnancy_exclusion BOOLEAN DEFAULT TRUE,
  smoking_status VARCHAR(50), -- "current_smoker_excluded", "any", "former_only"
  other_criteria JSONB, -- Additional criteria (structured as JSON)
  created_at TIMESTAMP DEFAULT NOW()
);

-- Patient Trial Matches
CREATE TABLE patient_trial_matches (
  id SERIAL PRIMARY KEY,
  patient_id INTEGER REFERENCES wp_users(ID),
  trial_id INTEGER REFERENCES clinical_trials(id),
  match_score INTEGER, -- 0-100%
  match_category VARCHAR(20), -- "highly_likely", "likely", "possible", "unlikely"
  criteria_met JSONB, -- Detailed breakdown of which criteria met/not met
  match_date DATE DEFAULT NOW(),
  patient_notified BOOLEAN DEFAULT FALSE,
  patient_interest VARCHAR(20), -- "interested", "not_interested", "maybe", NULL
  patient_enrolled BOOLEAN DEFAULT FALSE,
  enrollment_date DATE,
  created_at TIMESTAMP DEFAULT NOW()
);

-- Research Consent
CREATE TABLE research_consent (
  id SERIAL PRIMARY KEY,
  patient_id INTEGER REFERENCES wp_users(ID),
  consent_type VARCHAR(50), -- "all_research", "specific_trial_only"
  specific_trial_id INTEGER REFERENCES clinical_trials(id), -- If specific trial only
  consent_granted BOOLEAN DEFAULT TRUE,
  consent_date DATE DEFAULT NOW(),
  withdrawal_date DATE, -- If consent withdrawn
  created_at TIMESTAMP DEFAULT NOW()
);

-- Travel Grants
CREATE TABLE travel_grants (
  id SERIAL PRIMARY KEY,
  patient_id INTEGER REFERENCES wp_users(ID),
  trial_id INTEGER REFERENCES clinical_trials(id),
  visit_dates DATE[],
  distance_miles INTEGER,
  amount_requested DECIMAL(10, 2),
  amount_approved DECIMAL(10, 2),
  status VARCHAR(20) DEFAULT 'pending', -- "pending", "approved", "denied", "paid"
  expenses_breakdown JSONB, -- {"airfare": 450, "hotel": 300, "meals": 100}
  financial_need_explanation TEXT,
  reviewed_by INTEGER REFERENCES wp_users(ID),
  review_date DATE,
  created_at TIMESTAMP DEFAULT NOW()
);

-- Researcher Recruitment Campaigns
CREATE TABLE recruitment_campaigns (
  id SERIAL PRIMARY KEY,
  trial_id INTEGER REFERENCES clinical_trials(id),
  researcher_id INTEGER REFERENCES wp_users(ID),
  message_template TEXT,
  patients_contacted INTEGER DEFAULT 0,
  patients_opened INTEGER DEFAULT 0,
  patients_clicked INTEGER DEFAULT 0,
  patients_expressed_interest INTEGER DEFAULT 0,
  patients_enrolled INTEGER DEFAULT 0,
  campaign_date DATE DEFAULT NOW(),
  created_at TIMESTAMP DEFAULT NOW()
);
```

---

### ClinicalTrials.gov API Integration

```javascript
// Node.js - Ingest trials from ClinicalTrials.gov
const axios = require('axios');

async function ingestAlpha1Trials() {
  // Search ClinicalTrials.gov for Alpha-1 trials
  const response = await axios.get(
    'https://clinicaltrials.gov/api/query/full_studies',
    {
      params: {
        expr: 'alpha-1 antitrypsin deficiency',
        fmt: 'json',
        min_rnk: 1,
        max_rnk: 100
      }
    }
  );

  const studies = response.data.FullStudiesResponse.FullStudies;

  for (const study of studies) {
    const protocolSection = study.Study.ProtocolSection;
    const nctId = protocolSection.IdentificationModule.NCTId;

    // Check if trial already exists
    const existing = await db.query(
      'SELECT * FROM clinical_trials WHERE nct_id = $1',
      [nctId]
    );

    if (existing.rows.length === 0) {
      // Insert new trial
      await db.query(
        `
        INSERT INTO clinical_trials (nct_id, title, sponsor, phase, status, description, eligibility_criteria, start_date, completion_date)
        VALUES ($1, $2, $3, $4, $5, $6, $7, $8, $9)
      `,
        [
          nctId,
          protocolSection.IdentificationModule.OfficialTitle,
          protocolSection.SponsorCollaboratorsModule.LeadSponsor
            .LeadSponsorName,
          protocolSection.DesignModule.PhaseList?.Phase[0] || 'N/A',
          protocolSection.StatusModule.OverallStatus,
          protocolSection.DescriptionModule.BriefSummary,
          protocolSection.EligibilityModule.EligibilityCriteria,
          protocolSection.StatusModule.StartDateStruct?.StartDate,
          protocolSection.StatusModule.PrimaryCompletionDateStruct
            ?.PrimaryCompletionDate
        ]
      );

      console.log(`Ingested trial: ${nctId}`);
    } else {
      console.log(`Trial ${nctId} already exists, skipping`);
    }
  }

  console.log(`Ingestion complete: ${studies.length} trials processed`);
}

// Run weekly via cron job
const cron = require('node-cron');
cron.schedule('0 0 * * 0', ingestAlpha1Trials); // Every Sunday at midnight
```

---

## ğŸ’µ Budget Breakdown

### Development Costs

| Component                               | Hours         | Rate | Cost         |
| --------------------------------------- | ------------- | ---- | ------------ |
| Trial matching engine                   | 250           | $120 | $30,000      |
| Patient portal (trial search, matching) | 180           | $100 | $18,000      |
| Researcher dashboard                    | 200           | $100 | $20,000      |
| ClinicalTrials.gov API integration      | 100           | $120 | $12,000      |
| Consent management system               | 80            | $100 | $8,000       |
| Travel grants application system        | 60            | $100 | $6,000       |
| Research education hub (videos, FAQs)   | 60            | $100 | $6,000       |
| Analytics dashboard                     | 80            | $100 | $8,000       |
| QA & Testing                            | 70            | $85  | $5,950       |
| PM & Documentation                      | 60            | $85  | $5,100       |
| Contingency (15%)                       | -             | -    | $17,858      |
| **Total Development**                   | **1,140 hrs** | -    | **$136,908** |

### Annual Operating Costs

| Item                          | Cost         | Notes                                        |
| ----------------------------- | ------------ | -------------------------------------------- |
| Research coordinator          | $75,000      | Full-time, manage matching, patient outreach |
| Travel grants program         | $40,000      | 50-60 grants @ $500-$1,500 each              |
| Platform maintenance          | $10,000      | Updates, bug fixes                           |
| ClinicalTrials.gov monitoring | $6,000       | Weekly checks for new trials                 |
| Consent management/compliance | $6,000       | HIPAA audit, legal review                    |
| Patient education materials   | $6,000       | Update videos, print materials               |
| IRB/ethics consultation       | $8,000       | Ensure ethical recruitment                   |
| **Total Annual**              | **$151,000** | -                                            |

### 3-Year Projection

| Year      | Dev (amortized) | Operating    | Revenue        | Net           |
| --------- | --------------- | ------------ | -------------- | ------------- |
| Year 1    | $136,908        | $151,000     | $225,000       | -$62,908      |
| Year 2    | -               | $151,000     | $369,000       | +$218,000     |
| Year 3    | -               | $151,000     | $500,000       | +$349,000     |
| **Total** | **$136,908**    | **$453,000** | **$1,094,000** | **+$504,092** |

**ROI**: 85% over 3 years

---

## ğŸ“Š Success Metrics

### Primary KPIs (Year 1)

**Trial Matching**:

- **500 patients matched to trials** (from 200/year = 2.5x)
- **200 patients enrolled in trials** (from 80/year = 2.5x)
- **15% enrollment rate** (from 5% = 3x conversion)
- **20 active trials** listed on platform

**Researcher Impact**:

- **50% reduction in recruitment time** (24 months â†’ 12 months avg.)
- **30% reduction in screening failures** (better pre-screening)
- **10 pharma/academic clients** using researcher dashboard

**Patient Impact**:

- **50 travel grants awarded** ($500-$1,500 each)
- **4.5/5 patient satisfaction** ("Easy to find trials I qualify for")

### Secondary KPIs

**Platform Engagement**:

- **3,000 patient portal users** (37% of Registry)
- **80% consent to research** contact (maintain high opt-in rate)
- **60% of matched patients** click "Learn More" (engagement metric)

**Research Advancement**:

- **5 trials complete enrollment ahead of schedule** (due to Alpha1Life recruitment)
- **3 new trials launched** (sponsors confident in recruitment â†’ greenlight more studies)

---

## âš ï¸ Risks & Mitigation

### Ethical Risks

**Risk 1: Coercive Recruitment**

- Patients feel pressured to enroll in trials
- Risk: Violates research ethics, IRB sanctions

**Mitigation**:

- âœ… IRB review of all recruitment materials
- âœ… Clear opt-out options (every email, easy to withdraw consent)
- âœ… No financial incentives for enrollment (only travel reimbursement)
- âœ… Emphasize: "It's OK to say no. This is your choice."

**Risk 2: Privacy Breach (Researcher Access to Patient Data)**

- Researchers see PHI without patient consent
- Risk: HIPAA violation, $50K+ fines

**Mitigation**:

- âœ… De-identified search results (researchers see counts, not names)
- âœ… Patients opt-in to research contact (explicit consent)
- âœ… Researchers can only message patients who consented
- âœ… Audit trail: Log all researcher queries, patient contacts

---

### Operational Risks

**Risk 3: Trial Ingestion Errors**

- ClinicalTrials.gov data incorrect or incomplete
- Risk: Match patients to wrong trials, waste everyone's time

**Mitigation**:

- âœ… Manual review: Research coordinator checks all ingested trials
- âœ… Structured eligibility: Researchers enter structured criteria (not just free-text)
- âœ… Disclaimer: "Final eligibility confirmed by study team"

**Risk 4: Low Patient Opt-In to Research**

- Patients don't consent to research contact (fear, distrust)
- Risk: Small patient pool, platform not useful

**Mitigation**:

- âœ… Granular consent: "Opt into all research" or "specific trials only"
- âœ… Education: Videos explaining research participation benefits
- âœ… Transparency: Show patients exactly what researchers see (de-identified)

---

## ğŸš€ Go-to-Market Strategy

### Launch Plan (Q1-Q3 2026)

**Pre-Launch (Jan-Mar 2026)**:

- Build platform (trial matching, researcher dashboard)
- Ingest 20 active Alpha-1 trials from ClinicalTrials.gov
- Pilot with 3 academic researchers (get feedback)

**Soft Launch (Apr-Jun 2026)**:

- Email 8,000 Registry patients: "Find trials you qualify for"
- 80% opt-in to research contact (target)
- Match 100 patients to trials (pilot goal)

**Full Launch (Jul 2026)**:

- Press release: "Alpha1Life Revolutionizes Trial Recruitment"
- Pitch pharma sponsors (Grifols, CSL Behring, Arrowhead): $15K/year access fee
- Target: 200 enrollments Year 1

---

### Marketing Tactics

**Patient Recruitment**:

- **Email**: "You May Qualify for a Clinical Trial" (targeted to eligible patients)
- **Patient stories**: "I enrolled in a gene therapy trial and it changed my life"
- **Conference**: Promote at Alpha1Life annual conference (800 attendees)

**Researcher Outreach**:

- **Direct sales**: Pitch pharma sponsors, academic PIs
- **Conferences**: Exhibit at ATS, CHEST (researchers see demo)
- **Publications**: Publish case study in _Respiratory Research_ ("How Alpha1Life tripled trial enrollment")

---

## ğŸ”® Future Enhancements (Year 3-5)

### Advanced Features

**AI-Powered Matching**:

- Machine learning predicts which patients most likely to enroll (not just eligible)
- Optimize outreach timing, messaging

**Virtual Trial Support**:

- Telehealth visits for trial participants (reduce travel burden)
- At-home blood draws, mobile PFT technicians

**Global Expansion**:

- European trial matching (2027, partner with ERS)
- Latin American trials (2028)

**Real-World Evidence Platform**:

- Collect data from trial participants post-trial (long-term outcomes)
- Share with FDA, pharma (accelerate drug approvals)

---

## ğŸ“š Comparable Examples

### Successful Trial Matching Platforms

**1. TrialX** (General, all diseases):

- 3M+ patients, 150K+ trials
- **Lesson**: Automated matching scales recruitment

**2. CISCRP** (Clinical trials education):

- Patient education â†’ 40% increase in trial awareness
- **Lesson**: Education reduces fear, increases enrollment

**3. PatientsLikeMe** (Patient registry + research):

- 830K+ patients, 100+ research partnerships
- **Lesson**: Patients trust patient-led platforms more than pharma

**4. Cystic Fibrosis Foundation Patient Registry**:

- 90% of CF patients enrolled, used for trial recruitment
- **Lesson**: Disease-specific registries = gold standard for rare disease research

---

## ğŸ“ Next Steps

### Phase 1: Development (Months 1-4)

**Month 1-2**:

- [ ] Present to MEF board
- [ ] Budget approval ($137K dev + $151K/year operating)
- [ ] Hire research coordinator (full-time)

**Month 3-4**:

- [ ] Build trial matching engine
- [ ] Ingest 20 trials from ClinicalTrials.gov
- [ ] IRB approval for recruitment practices

### Phase 2: Pilot (Months 5-6)

**Month 5**:

- [ ] Pilot with 3 academic trials (100 patients matched)
- [ ] Gather feedback (patients + researchers)

**Month 6**:

- [ ] Iterate on platform (fix bugs, improve UX)
- [ ] Recruit 2 pharma sponsors ($30K revenue)

### Phase 3: Full Launch (Month 7+)

**Month 7**:

- [ ] Email 8,000 Registry patients ("Find your trial")
- [ ] Target: 80% opt-in to research contact

**Month 12**:

- [ ] Year 1 review: 200 enrollments (2.5x baseline)

---

## ğŸ¯ Success Criteria (12-Month Review)

### Must Achieve (Year 1)

- âœ… **500 patients matched to trials**
- âœ… **200 patients enrolled** (2.5x increase)
- âœ… **15% enrollment rate** (triple conversion)
- âœ… **20 active trials** listed

### Should Achieve

- âœ… **50% reduction in recruitment time** (24 â†’ 12 months)
- âœ… **10 pharma/academic clients** (researcher dashboard)
- âœ… **50 travel grants awarded**

### Stretch Goals

- âœ… **300 enrollments** (3.75x increase)
- âœ… **5 trials complete ahead of schedule**
- âœ… **$300K revenue** (exceed projections)

---

## ğŸ’¡ Why This Matters

**Research is how we find a cure.** But research can't happen without patients. **This platform is the bridge between patients who want to help and scientists who need them.**

**Imagine**:

- A 38-year-old woman, PI*ZZ, FEV1 52%, gets an email: *"You may qualify for a gene therapy trial."\* She clicks. She reads. She enrolls. **18 months later, her AAT levels triple. Her FEV1 stabilizes. She's living proof gene therapy works. The FDA approves it based on her data. 10,000 patients get access.**

- A pharma company hesitates to launch an Alpha-1 trial. _"Can we recruit enough patients?"_ They see Alpha1Life's platform: _"8,000 registered patients, automated matching, 15% enrollment rate."_ **They greenlight the trial. $50M invested in Alpha-1 research. Breakthrough treatment discovered.**

- A 50-year-old man, PI*ZZ, FEV1 35%, doesn't know trials exist. He gets matched to a trial 200 miles away. *"I can't afford travel."\* MEF grants him $1,500. **He enrolls. He helps prove the treatment works. His grandkids won't have Alpha-1 thanks to gene therapy.**

**This isn't just a platform. It's the engine that accelerates Alpha-1 research from decades to years. It's how we find a cure.**

---

**For Questions**: Contact MEF Research Team
**Document Owner**: VLX (GitHub Copilot)
**Last Updated**: November 12, 2025
**Status**: Ready for Board Review
